(AOF) – Guerbet announces 2023 turnover of 785.7 million euros, an increase of 4.3% over one year, 6.4% at constant exchange rate (CER) and 5.9% at comparable scope. The global specialist in contrast products and solutions for medical imaging welcomes a performance fueled “by both an increase in volumes and positive price effects”, highlighting the “strong acceleration in growth” in the 4th quarter (+17 .9% at CER), driven by the performance of the Americas zone, at +39%.
Guerbet expects growth in excess of 8% at constant scope and CER in 2024, and confirms the objective of a restated EBITDA margin rate at a level higher than that of 2021 (14.4%). The group “expects significant growth in the contrast media market”.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
